Thalassemia is a genetic disorder characterized by a defect in the synthesis of globin, one of the main proteins that make up hemoglobin. This results in a deficiency of one or more types of globin chains (alpha or beta), which in turn causes anemia, excess iron accumulation in the body, and various morphological changes in red blood cells. Thalassemia is divided into several types, depending on the location and nature of the disorder, including α-thalassemia and β-thalassemia. These conditions have varying severity, from mild, requiring minimal treatment, to severe, requiring regular blood transfusions.
History of the disease and interesting historical facts
Thalassemia was first described in the early 20th century when in 1925 the Italian physician G. M. V. Calzonni noted a link between anemia and heredity in some areas of the Mediterranean. This opened up new horizons for the study and understanding of the disease. In the 1940s, it was established that thalassemia is a hereditary disease transmitted in an autosomal recessive manner. Interestingly, in some regions, especially among populations living along the Mediterranean coast, there is a high incidence of the disease, which is associated with natural selection. It is known that the carriage of mutations that cause thalassemia provides some protection against malaria, which explains the high prevalence of this disease in regions where malaria was endemic.
Epidemiology
According to the World Health Organization, thalassemia is one of the most common genetic abnormalities. It is estimated that there are more than 100 million carriers of thalassemia genes worldwide. The incidence of the disease varies depending on the geographic region:
- Mediterranean region: 1-2% population.
- Southeast Asia: up to 30% carriers.
- Middle East: 5-10% population has inherited mutations.
- Northern Europe: much lower prevalence (less than 1%).
These statistics show the need for early diagnosis and treatment of this condition, especially in areas where the prevalence of thalassemia is high.
Genetic predisposition to this disease
Thalassemia is caused by mutations in the genes responsible for globin synthesis. The main genes involved are:
- The genes for α-thalassemia are HBA1 and HBA2, located on chromosome 16.
- β-thalassemia genes: HBB, located on chromosome 11.
Mutations can range from small point substitutions to larger deletions, which affects the severity of the disease and its clinical manifestations. People with β-thalassemia can exhibit different phenotypes depending on the number of functioning copies of the gene.
Risk factors for the development of this disease
Risk factors that contribute to the development of thalassemia are mainly related to genetic predisposition. These include:
- Heredity: the presence of patients in the family or among ancestors.
- Ethnicity: Increased risk in people of the Mediterranean, Middle East, and Southeast Asia.
- Presence of other genetic disorders that may interact with thalassemia.
However, physical and chemical factors, such as exposure to certain toxins or radiation, do not play a significant role in the development of thalassemia.
Diagnosis of this disease
Diagnosis of thalassemia is based on the clinical picture, as well as laboratory and radiological studies. The main symptoms of the disease are:
- Fatigue and weakness.
- Pallor of the skin and mucous membranes.
- Short-term or persistent episodes of abdominal or ligament pain.
Laboratory tests help determine the type of anemia, including a complete blood count, biochemistry, and special tests such as hemoglobin electrophoresis. Radiologic tests may include x-rays that show changes in bone (such as widened ribs). The differential diagnosis includes various forms of anemia and other inherited blood disorders.
Treatment
Treatment for thalassemia may vary depending on the type and severity of the disease. Common approaches include:
- Regular blood transfusions to correct anemia.
- Chelation therapy to reduce iron levels in the body.
- Supportive therapy, including vitamins and minerals.
Pharmacological treatment often includes iron-lowering drugs such as deferoxamine or deferiprone. In advanced cases, surgery, including bone marrow transplantation, may be indicated.
List of medications used to treat this disease
The most common drugs include:
- Deferoxamine (Desferal)
- Deferiprone (Ferriprox)
- Hydroxyurea (Hydrea)
These agents help control iron levels and improve the overall condition of the patient.
Disease monitoring
Monitoring consists of regular examinations of hemoglobin levels, general health status, and iron levels. The prognosis for patients with thalassemia depends on the type and severity of the disease, as well as the adequacy of the treatment received. Possible complications include the development of cardiovascular diseases, endocrine disorders, and other health problems.
Age-related features of the disease
The course of thalassemia in different age groups has its own characteristics. In newborns and infants, the disease may be asymptomatic and manifest itself only during the first examination. In children and adolescents, growth retardation and the development of iron overload due to regular transfusions may be observed. In adults, additional complications often arise that require more careful monitoring.
Questions and Answers
- What is thalassemia? Thalassemia is a genetic disorder associated with a defect in the synthesis of globin, which leads to anemia and excess iron in the body.
- How is thalassemia diagnosed? Diagnosis is based on clinical presentation, laboratory tests and hemoglobin electrophoresis.
- How is thalassemia treated? Treatment includes blood transfusions, chelation therapy, and supportive care to control iron levels.
- Who is at risk for thalassemia? At risk are carriers of thalassemia genes and people from endemic regions: the Mediterranean, the Middle East, Southeast Asia.
- What is the prognosis of thalassemia treatment? The prognosis depends on the type of thalassemia and the effectiveness of the treatment received; properly treated patients can have a good life.
